Ocasio, Cory A. http://orcid.org/0000-0002-4957-4131
Baggelaar, Marc P. http://orcid.org/0000-0002-9784-6250
Sipthorp, James
Losada de la Lastra, Ana
Tavares, Manuel http://orcid.org/0000-0002-3048-5331
Volarić, Jana
Soudy, Christelle
Storck, Elisabeth M.
Houghton, Jack W.
Palma-Duran, Susana A.
MacRae, James I. http://orcid.org/0000-0002-1464-8583
Tomić, Goran
Carr, Lotte
Downward, Julian http://orcid.org/0000-0002-2331-4729
Eggert, Ulrike S. http://orcid.org/0000-0003-0932-5525
Tate, Edward W. http://orcid.org/0000-0003-2213-5814
Funding for this research was provided by:
Cancer Research UK (C29637/A27506, NS/A000078/1, C29637/A20183, DRCNPG-Nov21\100001, C24523/A27435, C24523/A27435, C29637/A27506)
Wellcome Trust (103799/Z/14/Z, 110060/Z/15/Z)
European Research Council Advanced Grant RASImmune
RCUK | Engineering and Physical Sciences Research Council (NS/A000078/1)
Article History
Received: 25 May 2022
Accepted: 13 October 2023
First Online: 8 January 2024
Competing interests
: E.W.T. is a founder and shareholder in Myricx Pharma and receives consultancy or research funding from Kura Oncology, Pfizer, Samsara Therapeutics, Myricx Pharma, Merck Sharp and Dohme (MSD), Exscientia and Daiichi Sankyo. J.D. has acted as a consultant for AstraZeneca, Jubilant, Theras, BridgeBio and Vividion and receives research funding from Bristol Myers Squibb and Revolution Medicines. The other authors declare no competing interests.